CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Chengdu Easton Biopharmaceuticals Co., Ltd. Share Price
Equities
688513
CNE100004397
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.58 CNY | +0.71% |
|
+4.61% | -5.02% |
| Sales 2024 * | 1.45B 201M 16B | Sales 2025 * | 1.77B 245M 19.48B | Capitalization | 7.21B 996M 79.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 291M 40.19M 3.2B | Net income 2025 * | 362M 50M 3.98B | EV / Sales 2024 * | 4.96 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.07 x |
| P/E ratio 2024 * |
25
x | P/E ratio 2025 * |
20.1
x | Employees | 1,400 |
| Yield 2024 * |
1.25% | Yield 2025 * |
1.5% | Free-Float | 45.41% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.71% | ||
| 1 week | +4.61% | ||
| Current month | +5.85% | ||
| 1 month | +5.85% | ||
| 3 months | +18.25% | ||
| 6 months | +11.98% | ||
| Current year | -5.02% |
1 week
56.69
61.29
1 month
54.8161.39
Current year
43.4163.87
1 year
43.4164.25
3 years
41.8565.88
5 years
41.8588.00
10 years
41.8588.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Xu Yuan
CEO | Chief Executive Officer | 53 | 31/12/08 |
Ying Wang
FOU | Founder | 58 | 31/05/09 |
Jia Yu Zhu
CHM | Chairman | 44 | 31/12/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Wu Geng
BRD | Director/Board Member | 56 | 22/12/21 |
Ying Wang
FOU | Founder | 58 | 31/05/09 |
Da Ming Zhang
BRD | Director/Board Member | 52 | 31/12/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 60.58 | +0.71% | 574,704 |
| 29/04/24 | 60.15 | +4.35% | 844,075 |
| 26/04/24 | 57.64 | -3.17% | 823,828 |
| 25/04/24 | 59.53 | +0.30% | 458,844 |
| 24/04/24 | 59.35 | -1.05% | 391,024 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The Company operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
60.58
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.02% | 996M | |
| +29.68% | 681B | |
| +20.11% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +14.38% | 235B | |
| +4.39% | 199B | |
| -11.62% | 189B | |
| -3.79% | 157B |
- Stock Market
- Equities
- 688513 Stock
